Response to Andrew Jack's article "Back to the Lab" | Diaceutics

Response to Andrew Jack’s article “Back to the Lab”

August 21st, 2013

Peter Keeling

Andrew Jack’s article “Back to the Lab” in the Financial Times (FT) on the 16th August 2013 ( ) captured some of the step change underway within Pharma R&D as it embraces personalized medicine. However, I was extremely disappointed that Mr Jack left out two critical insights which would have articulated to FT readers the long term business model implications of personalized medicine to the pharmaceutical industry.

The first is that targeted therapies are predominantly dependent upon companion diagnostics for their financial success. For example, the underperformance of Pfizer’s Xalkori is to a large extent due to a poor commercial strategy of the prerequisite ALK test. This has significant implications for long term supply chain management.

Secondly, the triple economic dividend from personalized medicines of smaller clinical trials, accelerated FDA approval and (when planned effectively) a diagnostic-enabled market pull delivering faster peak sales, are changing the fabric of pharma ROI.

Both of these deserve accurate reporting in future FT reviews.


View all blogs

Webinars & Podcasts

July 5th, 2019
Liquid Biopsy in NSCLC
August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Case Studies

View all case studies


June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications